NEW YORK – Oncocyte announced on Friday it has reached definitive agreements with institutional investors that will purchase about $10.7 million of the company's common shares in a registered offering.
The investors, which include Blackcrane Capital, will purchase the shares at an at-the-market price of $2.27 per share, the closing price of Oncocyte's stock immediately preceding the offering. Oncocyte is selling about 4.7 million shares in the offering, which is expected to close next week.